echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Lancet Oncol: The susceptible genetic variation of cervical precancerous lesions and invasive cervical cancer!

    Lancet Oncol: The susceptible genetic variation of cervical precancerous lesions and invasive cervical cancer!

    • Last Update: 2021-04-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Most cervical high-risk human papillomavirus (HPV) infections are transient, and only a small percentage of HPV-infected people will develop cervical cancer.


    Infection Why some people who are infected with HPV can heal themselves, while some people will develop cervical cancer?

    Family clustering studies and heritability assessments indicate that this may be mediated by genetic factors.


    GWAS

    This study used a genome-wide approach to compare the differences in gene mutations between invasive cervical cancer and cervical intraepithelial neoplasia (CIN) grade 3 patients and healthy controls .


    Comparing the differences in gene mutations between invasive cervical cancer and cervical intraepithelial neoplasia (CIN) grade 3 patients and healthy controls

    Researchers used data from the UK Biobank to conduct GWAS inspections on a group of unrelated Europeans, including 273377 recruited between March 13, 2006 and October 1, 2010, between 40 and 69 years old.


    Overall, this study included 4769 CIN3 and invasive cervical cancer case samples and 145,545 control samples from GWAS.


    Independent variants associated with CIN grade 3 and invasive cervical cancer

    Independent variants associated with CIN grade 3 and invasive cervical cancer

    Among the 9,600,464 single nucleotide polymorphisms (SNP) sites analyzed, 6 independent variants were associated with CIN level 3 and invasive cervical cancer .


    Among the 9600464 single nucleotide polymorphisms (SNP) sites analyzed, 6 independent variants are associated with CIN3 grade and invasive cervical cancer PAX8 -9 CLPTM1L -9 HLA-DQA1 -28 MICA -17 HLA-DQB1 –22 HLA-B -6

    Three SNPs were captured in the independent data set of 1648 cases of invasive cervical cancer: Pax8 (rs10175462; p=0.


    Three SNPs were captured in an independent data set of 1648 cases of invasive cervical cancer: Pax8 CLPTM1L -7 HLA-DQA1 -8

    Mendelian randomization analysis further supports smoking (OR 2.


    Smoking at first pregnancy, older age and more sex partners , all contribute to the risk of cervical cancer

    In summary, the results of this study provide new evidence for the genetic susceptibility of cervical cancer, especially PAX8, CLPTM1L and HLA genes, suggesting that the interference of apoptosis and immune function pathways may play an important role in the occurrence of cervical cancer .


    The genetic susceptibility to cervical cancer study results provide new evidence, especially PAX8, CLPTM1L and HLA gene, suggesting that apoptosis and immune function may be disturbed pathways play an important role in the occurrence of cervical cancer immunization

    Original source:

    Original source:

    Bowden Sarah J, Bodinier Barbara, Kalliala Ilkka et al.


    org/10.
    1016/S1470-2045(21)00028-0" target="_blank" rel="noopener">Genetic variation in cervical preinvasive and invasive disease : a genome-wide association study in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.